Literature DB >> 23720829

Introduction to the CANWARD study (2007–11).

Daryl J Hoban1, George G Zhanel.   

Abstract

Antimicrobial resistance is a continuing challenge to the appropriate, timely, cost-effective and ecologically appropriate delivery of antimicrobials. Surveillance studies conducted globally and nationally can assist in determining trends over specific geographical areas and allow comparisons between countries and within very specific infectious processes. CANWARD is an ongoing, national, Health Canada-endorsed, multiyear study focused on both inpatient and outpatient pathogens isolated in Canadian hospitals and determining their degree of antimicrobial resistance, with a particular emphasis on specific wards (medical, surgical, intensive care units, emergency room and clinics) as well as specific infection sites (urine, blood, respiratory and wound). This Supplement documents the initial 5 years of the CANWARD study (2007–11 inclusive). The seven manuscripts in this Supplement provide a comprehensive examination of pathogens covering multiple infectious processes. The data highlight the continued emergence of resistance and should provide to healthcare professionals nationally and globally the current status of antimicrobial resistance in Canada.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23720829     DOI: 10.1093/jac/dkt021

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  A niclosamide-tobramycin hybrid adjuvant potentiates cefiderocol against P. aeruginosa.

Authors:  Liam Berry; Marc Brizuela; Gregory Jackson; Frank Schweizer
Journal:  RSC Med Chem       Date:  2021-07-27

2.  Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.

Authors:  Liam Berry; Ronald Domalaon; Marc Brizuela; George G Zhanel; Frank Schweizer
Journal:  Medchemcomm       Date:  2019-03-07       Impact factor: 3.597

3.  Dioctanoyl Ultrashort Tetrabasic β-Peptides Sensitize Multidrug-Resistant Gram-Negative Bacteria to Novobiocin and Rifampicin.

Authors:  Danyel Ramirez; Liam Berry; Ronald Domalaon; Yanqi Li; Gilbert Arthur; Ayush Kumar; Frank Schweizer
Journal:  Front Microbiol       Date:  2021-12-23       Impact factor: 5.640

4.  Effects of Lysine N-ζ-Methylation in Ultrashort Tetrabasic Lipopeptides (UTBLPs) on the Potentiation of Rifampicin, Novobiocin, and Niclosamide in Gram-Negative Bacteria.

Authors:  Linus Schweizer; Danyel Ramirez; Frank Schweizer
Journal:  Antibiotics (Basel)       Date:  2022-03-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.